Xeris Glucagon Filing Accepted by FDA; June 10, 2019 PDUFA

Xeris Pharmaceuticals announced FDA has accepted the NDA filing for its stable glucagon with a PDUFA date on Monday, June 10, 2019, the Monday of ADA. This confirms FENIX’s previous belief that Xeris’s stable glucagon would have a 10-month review period. Below, FENIX provides thoughts on Xeris’s later-than-anticipated regulatory submission and impending market dynamics in the glucagon rescue market.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.